Molsentech

What Molsentech does

Molsentech (矽基分子電測科技股份有限公司 / Silicon Based Molecular Sensing Technology Co., Ltd.) is a Taiwan-based deep-tech company founded in 2014 that develops a semiconductor biochip detection platform based on Silicon Nanowire Field-Effect Transistor (SiNW-FET) Bio-FET technology. The platform integrates semiconductor chip manufacturing, proprietary molecular modification and bio-coating techniques, and microfluidic systems to enable label-free, amplification-free molecular detection that delivers results in under 30 minutes at sensitivity of 3 copies/ml, versus 1-4 hours for PCR and 2-5 hours for ELISA. Molsentech has translated this core technology into products including a TFDA-EUA-approved COVID-19 nucleic acid detection chip, a Pet Cancer Screening Chip with 4-in-1 multiplex biomarker detection, a Multiplex Respiratory Pathogen Detection platform, neurodegenerative disease screening chips, and precision medicine/AMR monitoring chips, plus a Fully Automated Biomedical Chip Detection Platform launched in 2024.

The company's product surface is anchored in proprietary technical components: a SiNW-FET biosensor that converts biomolecular binding into digital electrical signals, heterogeneous stacking packaging that reduces microfluidic clogging, proprietary bio-coating for molecular stability, and what the company describes as the world's first integrated current signal and fluid automation detection system. Manufacturing leverages standard silicon IC wafer fabrication through a co-development partnership with TSMC, which Molsentech states enables high yield and up to 50% cost savings versus traditional methods. The company maintains two sites in Taiwan: its headquarters in the National Biotechnology Research Park in Nangang, Taipei, and a Bio-Fab manufacturing facility established in 2025 at Baogao Smart Industrial Park in New Taipei City.

Molsentech operates a B2B sales-led, project-based revenue model with three primary streams: hardware sales of biochips and detection platforms, custom R&D and co-development services for pharmaceutical companies, research institutions, and hospitals, and licensing/technology transfer arrangements. Products are sold through dedicated R&D projects with custom pricing rather than public list pricing, and the company has no distribution or e-commerce channel. It targets four core verticals: healthcare institutions (hospitals and clinics requiring rapid POCT), biopharmaceutical and cell therapy companies (high-sensitivity detection, mycoplasma contamination testing), research institutions and universities (custom biomarker detection), and veterinary clinics (pet cancer screening). Notable named customers and partners include Kaohsiung Veterans General Hospital, Huayu Pharmaceutical, Academia Sinica, and National Applied Research Laboratories.

Name

Molsentech

Legal name

SILICON-BASED MOLECULAR SENSING TECHNOLOGY Co., Ltd.

Website

https://molsentech.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Molsentech is a Taiwan-based deep-tech company developing SiNW-FET Bio-FET semiconductor biochips for label-free, amplification-free molecular detection, serving hospitals, biopharma, research institutions, and veterinary clinics with rapid, low-cost diagnostic platforms.

Ownership category

akta.pro rank

Product category

Semiconductor Biochips / Molecular Diagnostics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)

akta.pro secondary industries

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Semiconductor biochips
• Molecular diagnostics
• Point-of-care testing
• Precision medicine
• Bio-FET biosensors

Headquarters

HQ city

Taipei City (Nangang District)

HQ country

Taiwan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Biochip and Detection Platform Sales: Sale of semiconductor biochips and integrated detection systems. Products include COVID-19 nucleic acid detection chips, pet cancer screening chips, and custom biochip development services. Revenue derived from both product sales and R&D collaboration project fees.
2. Custom R&D and Co-development Services: Custom biochip development projects for pharmaceutical companies, research institutions, and hospitals. Professional team provides in-depth optimization and customization for specific detection targets. Collaborative development model with partners.
3. Licensing and Technology Transfer: Technology partnerships with semiconductor manufacturers (TSMC co-development), pharmaceutical companies (cancer detection), and international research institutions. Technology licensing based on Bio-FET platform.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels8 records

Core offering

Molsentech develops and sells semiconductor biochips and integrated detection platforms based on its proprietary SiNW-FET (Silicon Nanowire Field-Effect Transistor) Bio-FET technology, enabling label-free, amplification-free molecular detection with results in under 30 minutes. The company offers dedicated biochips for COVID-19, pet cancer screening, multiplex respiratory pathogens, antimicrobial resistance, and neurodegenerative disease biomarkers, alongside custom biochip development services for pharmaceutical, clinical, and research customers. Core distribution is direct enterprise sales and co-development partnerships rather than retail or consumer channels.

Product overview

Molsentech offers a Bio-FET semiconductor biochip platform-based product portfolio centered on SiNW-FET (Silicon Nanowire Field-Effect Transistor) technology. The product line includes dedicated detection chips for COVID-19 nucleic acid testing, pet cancer screening, multiplex respiratory pathogen detection, precision medicine with antimicrobial resistance monitoring, and neurodegenerative disease screening. These products share the core semiconductor biochip platform featuring label-free, amplification-free, real-time detection with results in under 30 minutes. The company also provides universal biomedical development chips as a standardized platform for custom probe integration, along with customized biochip development services. The technology combines microfluidic systems with semiconductor manufacturing processes to enable decentralized point-of-care testing (POCT).

Differentiator

Problem solved

Functional benefit

Products and services

• COVID-19 Nucleic Acid Detection Chip Semiconductor biochip for rapid nucleic acid detection of COVID-19 with sensitivity of 3 copies/ml, delivering results within 20 minutes without genetic amplification. Targets hospitals, clinics, and frontline medical institutions.
• Pet Cancer Screening Chip Companion animal cancer screening platform with 4-in-1 multiplex detection for simultaneous analysis of four cancer biomarkers, achieving 90.9% sensitivity and 83.3% specificity. Designed for veterinary hospitals and clinics.
• Multiplex Respiratory Pathogen Detection Biochip Biochip platform for rapid detection of major respiratory pathogens including COVID-19, influenza viruses, and Streptococcus pneumoniae. Targets hospitals and clinical labs requiring decentralized point-of-care testing.
• Universal Biomedical Development Chips Standardized semiconductor biochip platform supporting custom probe integration (DNA, RNA, proteins, antibodies) for diverse forward-looking research applications. Targets research institutions and pharmaceutical companies.
• Precision Medicine & Antimicrobial Resistance Monitoring Biochip Biochip for detection of antibiotic resistance genes and drug response monitoring to support personalized medication decisions. Targets hospitals and clinical pharmacies for antimicrobial stewardship.
• Neurodegenerative Disease Screening Chip Biochip platform for high-sensitivity detection of dementia biomarkers including Alzheimer's disease. Targets clinical research institutions and memory clinics for early-stage screening.
• Customized Biochip Development Services Custom biochip development service offering target selection, diverse probe support (DNA, RNA, proteins, antibodies), multiplex detection, signal processing optimization, and application-adapted solutions for clinical, veterinary, and environmental monitoring. Targets pharmaceutical companies, research institutions, and hospitals.
• Fully Automated Biomedical Chip Detection Platform Fully automated biomedical chip detection instrument that integrates the Bio-FET biochip with fluid automation and signal processing for application targets including leukemia and point-of-care testing.

Quantifiable outcome

• 96.8% sensitivity and 95.1% specificity for COVID-19 detection; 100% positive/negative agreement for clinical samples with Ct<35
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Eleven partnerships are on record, tiered strategic, major and core.

• UC Berkeley School of Public HealthstrategicStrategic or Co-development Partner · 1 January 2024Selected for training program co-organized by National Development Council and UC Berkeley School of Public Health in 2024, representing international academic collaboration for market expansion.
• J.P. Morgan / UC Berkeley / Stanford Taiwan Science and Technology CenterstrategicGTM or Marketing Partner · 1 January 2024Selected to exhibit at healthcare conference co-organized by J.P. Morgan, UC Berkeley, and Stanford Taiwan Science and Technology Center in 2024, providing international market visibility and GTM opportunities.
• National Central University (中央大學)strategicStrategic or Co-development Partner · 6 October 2023Partner in National Central University's 'Space Biomedicine Ground Test Laboratory' announced October 2023, collaborating with ten companies on space biomedicine research and applications.
• Startup World Cup (SWC)strategicGTM or Marketing Partner · 5 October 2023Molsentech won Taiwan regional championship in Startup World Cup 2023 and represented Taiwan at global finals in the US competing for $1 million investment prize, providing significant global visibility and networking opportunities.
• Huayu Pharmaceutical (華宇藥品)majorStrategic or Co-development Partner · 8 September 2023Collaboration on cancer detection chip development announced in September 2023. Partnership aims to leverage Molsentech's Bio-FET technology platform for cancer biomarker detection, showcasing Taiwan's advantages in biomedical chip development.
• Academia Sinica (中央研究院)coreTechnology or Integration · 25 January 2022Core technology source for Bio-FET semiconductor biochip development. Academia Sinica's research provided the foundational silicon nanowire FET technology that Molsentech commercialized for biomedical detection applications.
• National Applied Research Laboratories (國研院)coreTechnology or Integration · 25 January 2022Strategic technology partner for COVID-19 chip development. National Applied Research Laboratories (NARLabs) supported pandemic response technology development alongside Academia Sinica and clinical partners.
• Kaohsiung Veterans General Hospital (高雄榮民總醫院)majorImplementation/ SI/ Consulting Partner · 25 January 2022Clinical validation partner for COVID-19 rapid detection chip development. Conducted clinical trials that validated chip performance leading to TFDA EUA approval in January 2022.
• MIT (Massachusetts Institute of Technology)strategicTechnology or Integration · 1 January 2022MIT developed and manufactured the world's first COVID-19 chip detection system using Molsentech's core biochip technology, announced January 2022. Represents international technology transfer and validation of Molsentech's Bio-FET platform.
• Merck (德國默克)strategicStrategic or Co-development Partner · 28 June 2019Selected for Merck Innovation Lab incubator program in June 2019. First collaboration between Merck and a local Taiwanese team, establishing an innovation lab focused on biomedical technology development.
• TSMC (台積電)coreStrategic or Co-development Partner · 1 January 2016Co-development agreement signed in 2016 for semiconductor biochip technology development. TSMC provides advanced semiconductor manufacturing process capabilities essential for Bio-FET chip fabrication. This is a foundational co-development partnership leveraging TSMC's IC mass production infrastructure.

Scale indicators11 records

Recent moves7 records

Expansion highlights12 records

Broad incumbents

• Hologic (Panther Fusion): Hologic's Panther Fusion and Aptima systems serve molecular diagnostics in women's health and infectious disease with broad regulatory coverage. A relevant broad incumbent in clinical molecular diagnostics against which Molsentech must position its speed and cost economics.
• bioMérieux (BioFire): bioMérieux's BioFire FilmArray platform leads multiplex molecular syndromic diagnostics for respiratory, gastrointestinal, and bloodstream infections. A relevant broad incumbent directly competing in multiplex respiratory pathogen detection — one of Molsentech's named product lines.
• Cepheid (Danaher): Cepheid's GeneXpert is the dominant rapid molecular PCR diagnostic platform with thousands of hospital placements globally. Relevant broad incumbent in molecular diagnostics against which Molsentech's faster, cheaper Bio-FET alternative must compete for clinical adoption.
• QuidelOrtho: QuidelOrtho's Sofia and Triage product lines lead rapid immunoassay-based POCT diagnostics with strong veterinary and clinical channels. Relevant as a POCT incumbent whose veterinary channel could overlap with Molsentech's pet cancer chip commercialization strategy.
• Roche Diagnostics: Roche Diagnostics operates cobas Liat and other rapid molecular platforms spanning centralized and POCT markets with extensive global hospital footprint. A relevant broad incumbent setting the standard for sensitivity, regulatory coverage, and clinical workflow integration.
• Abbott Diagnostics: Abbott operates i-STAT, ID NOW, and Alinity series covering POCT and centralized molecular diagnostics with deep hospital integration. A relevant broad incumbent competitor across Molsentech's target segments (respiratory pathogen detection, decentralized testing).

Direct peers

• Standard BioTools (formerly Fluidigm): Standard BioTools designs semiconductor and microfluidic-based life science tools (CyTOF, Biomark HD) for high-throughput multiplexed biological analysis. Directly comparable as a semiconductor/microfluidic-based biology detection platform, though with broader mass cytometry focus.
• Quanterix: Quanterix's Simoa platform enables ultra-sensitive single-molecule biomarker detection for neurology, oncology, and infectious disease. Comparable as a high-sensitivity biomarker detection platform pursuing multiplex decentralized diagnostics — closely aligned to Molsentech's neurodegenerative and cancer roadmap.
• T2 Biosystems: T2 Biosystems develops direct molecular detection platforms (T2MR) using proprietary non-PCR technology for rapid sepsis, Candida, and Lyme diagnostics. Directly comparable as a label-free, amplification-free molecular diagnostic platform competing against PCR incumbents.
• CardioMEMS (Abbott): CardioMEMS developed an implantable MEMS-based wireless pulmonary artery pressure sensor using semiconductor fabrication. Comparable as a semiconductor-fabricated BioMEMS biosensing technology, though focused on implantable physiological monitoring rather than in-vitro molecular diagnostics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/molsentech

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molsentech